These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 25684341)

  • 1. Employment of higher doses of botulinum toxin type A to reduce spasticity after stroke.
    Santamato A; Micello MF; Ranieri M; Valeno G; Albano A; Baricich A; Cisari C; Intiso D; Pilotto A; Logroscino G; Panza F
    J Neurol Sci; 2015 Mar; 350(1-2):1-6. PubMed ID: 25684341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety of repeated high doses of incobotulinumtoxinA injections for the treatment of upper and lower limb spasticity after stroke.
    Santamato A; Panza F; Intiso D; Baricich A; Picelli A; Smania N; Fortunato F; Seripa D; Fiore P; Ranieri M
    J Neurol Sci; 2017 Jul; 378():182-186. PubMed ID: 28566161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke.
    Santamato A; Panza F; Ranieri M; Frisardi V; Micello MF; Filoni S; Fortunato F; Intiso D; Basciani M; Logroscino G; Fiore P
    J Neural Transm (Vienna); 2013 Mar; 120(3):469-76. PubMed ID: 22955957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial.
    Gracies JM; Brashear A; Jech R; McAllister P; Banach M; Valkovic P; Walker H; Marciniak C; Deltombe T; Skoromets A; Khatkova S; Edgley S; Gul F; Catus F; De Fer BB; Vilain C; Picaut P;
    Lancet Neurol; 2015 Oct; 14(10):992-1001. PubMed ID: 26318836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians).
    Bensmail D; Hanschmann A; Wissel J
    J Med Econ; 2014 Sep; 17(9):618-25. PubMed ID: 24841450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High doses of incobotulinumtoxinA for the treatment of post-stroke spasticity: are they safe and effective?
    Santamato A; Ranieri M; Solfrizzi V; Lozupone M; Vecchio M; Daniele A; Greco A; Seripa D; Logroscino G; Panza F
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):843-6. PubMed ID: 27291256
    [No Abstract]   [Full Text] [Related]  

  • 7. Can botulinum toxin type A injection technique influence the clinical outcome of patients with post-stroke upper limb spasticity? A randomized controlled trial comparing manual needle placement and ultrasound-guided injection techniques.
    Santamato A; Micello MF; Panza F; Fortunato F; Baricich A; Cisari C; Pilotto A; Logroscino G; Fiore P; Ranieri M
    J Neurol Sci; 2014 Dec; 347(1-2):39-43. PubMed ID: 25263601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of incobotulinumtoxinA influencing the clinical efficacy in post-stroke spasticity.
    Zeuner KE; Deuschl G
    Expert Opin Drug Metab Toxicol; 2016; 12(4):457-66. PubMed ID: 26882333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigating muscle selection for botulinum toxin-A injections in adults with post-stroke upper limb spasticity.
    Baguley IJ; Nott MT; Turner-Stokes L; De Graaff S; Katrak P; McCrory P; de Abadal M; Hughes A
    J Rehabil Med; 2011 Nov; 43(11):1032-7. PubMed ID: 22031350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits and Risks of Non-Approved Injection Regimens for Botulinum Toxins in Spasticity.
    Santamato A; Panza F
    Drugs; 2017 Sep; 77(13):1413-1422. PubMed ID: 28726023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of AbobotulinumtoxinA (Dysport) for the Treatment of Hemiparesis in Adults With Upper Limb Spasticity Previously Treated With Botulinum Toxin: Subanalysis From a Phase 3 Randomized Controlled Trial.
    Marciniak C; McAllister P; Walker H; Brashear A; Edgley S; Deltombe T; Khatkova S; Banach M; Gul F; Vilain C; Picaut P; Grandoulier AS; Gracies JM;
    PM R; 2017 Dec; 9(12):1181-1190. PubMed ID: 28625615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome.
    Esquenazi A; Albanese A; Chancellor MB; Elovic E; Segal KR; Simpson DM; Smith CP; Ward AB
    Toxicon; 2013 Jun; 67():115-28. PubMed ID: 23220492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OnabotulinumtoxinA for Lower Limb Spasticity: Guidance From a Delphi Panel Approach.
    Esquenazi A; Alfaro A; Ayyoub Z; Charles D; Dashtipour K; Graham GD; McGuire JR; Odderson IR; Patel AT; Simpson DM
    PM R; 2017 Oct; 9(10):960-968. PubMed ID: 28286053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of neural lesion type on botulinum toxin dosage: a retrospective chart review.
    Phadke CP; Davidson C; Ismail F; Boulias C
    PM R; 2014 May; 6(5):406-11. PubMed ID: 24211697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity.
    Kaňovský P; Slawek J; Denes Z; Platz T; Comes G; Grafe S; Pulte I
    J Rehabil Med; 2011 May; 43(6):486-92. PubMed ID: 21533328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spotlight on botulinum toxin and its potential in the treatment of stroke-related spasticity.
    Kaku M; Simpson DM
    Drug Des Devel Ther; 2016; 10():1085-99. PubMed ID: 27022247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of OnabotulinumtoxinA 400 Units in Patients with Post-Stroke Upper Limb Spasticity: Final Report of a Randomized, Double-Blind, Placebo-Controlled Trial with an Open-Label Extension Phase.
    Abo M; Shigematsu T; Hara H; Matsuda Y; Nimura A; Yamashita Y; Takahashi K
    Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32085529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum Toxins Type A (Bont-A) in the Management of Lower Limb Spasticity in Children: A Systematic Literature Review and Bayesian Network Meta-analysis.
    Guyot P; Kalyvas C; Mamane C; Danchenko N
    J Child Neurol; 2019 Jun; 34(7):371-381. PubMed ID: 30803305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of incobotulinum toxin type A (NT 201-Xeomin) for the treatment of post-stroke lower limb spasticity: a prospective open-label study.
    Santamato A; Micello MF; Panza F; Fortunato F; Pilotto A; Giustini A; Testa A; Fiore P; Ranieri M; Spidalieri R
    Eur J Phys Rehabil Med; 2013 Aug; 49(4):483-9. PubMed ID: 23480980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of incobotulinumtoxinA in post-stroke upper-limb spasticity in Japanese subjects: results from a randomized, double-blind, placebo-controlled study (J-PURE).
    Masakado Y; Abo M; Kondo K; Saeki S; Saitoh E; Dekundy A; Hanschmann A; Kaji R;
    J Neurol; 2020 Jul; 267(7):2029-2041. PubMed ID: 32219557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.